Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 302

1.

Serum 8-hydroxydeoxyguanosine, a marker of oxidative DNA damage, is associated with mortality independent of inflammation in chronic kidney disease.

Dai L, Watanabe M, Qureshi AR, Mukai H, Machowska A, Heimbürger O, Barany P, Lindholm B, Stenvinkel P.

Eur J Intern Med. 2019 Oct;68:60-65. doi: 10.1016/j.ejim.2019.07.035. Epub 2019 Aug 9.

PMID:
31402276
2.

Health-related quality of life as predictor of mortality in end-stage renal disease patients: an observational study.

Pei M, Aguiar R, Pagels AA, Heimbürger O, Stenvinkel P, Bárány P, Medin C, Jacobson SH, Hylander B, Lindholm B, Qureshi AR.

BMC Nephrol. 2019 Apr 29;20(1):144. doi: 10.1186/s12882-019-1318-x.

3.

Differences in association of lower bone mineral density with higher coronary calcification in female and male end-stage renal disease patients.

Chen Z, Qureshi AR, Brismar TB, Ripsweden J, Haarhaus M, Barany P, Heimburger O, Lindholm B, Stenvinkel P.

BMC Nephrol. 2019 Feb 18;20(1):59. doi: 10.1186/s12882-019-1235-z.

4.

Inverse J-shaped relation between coronary arterial calcium density and mortality in advanced chronic kidney disease.

Mukai H, Dai L, Chen Z, Lindholm B, Ripsweden J, Brismar TB, Heimbürger O, Barany P, Qureshi AR, Söderberg M, Bäck M, Stenvinkel P.

Nephrol Dial Transplant. 2018 Dec 7. doi: 10.1093/ndt/gfy352. [Epub ahead of print]

PMID:
30534995
5.

Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease.

Feldreich T, Nowak C, Fall T, Carlsson AC, Carrero JJ, Ripsweden J, Qureshi AR, Heimbürger O, Barany P, Stenvinkel P, Vuilleumier N, Kalra PA, Green D, Ärnlöv J.

J Nephrol. 2019 Feb;32(1):111-119. doi: 10.1007/s40620-018-0556-5. Epub 2018 Nov 29.

6.

Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study.

Levin A, Nair D, Qureshi AR, Bárány P, Heimburger O, Anderstam B, Stenvinkel P, Bruchfeld A, Ungerstedt JS.

Nephron. 2018;140(4):249-256. doi: 10.1159/000492500. Epub 2018 Sep 25.

PMID:
30253414
7.

Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients.

Molanaei H, Qureshi AR, Heimbürger O, Lindholm B, Diczfalusy U, Anderstam B, Bertilsson L, Stenvinkel P.

BMC Pharmacol Toxicol. 2018 Jun 25;19(1):33. doi: 10.1186/s40360-018-0221-6.

8.

Uraemic symptom burden and clinical condition in women and men of ≥65 years of age with advanced chronic kidney disease: results from the EQUAL study.

van de Luijtgaarden MWM, Caskey FJ, Wanner C, Chesnaye NC, Postorino M, Janmaat CJ, Rao A, Torino C, Klinger M, Drechsler C, Heimburger O, Szymczak M, Evans M, Dekker FW, Jager KJ; EQUAL study investigators .

Nephrol Dial Transplant. 2019 Jul 1;34(7):1189-1196. doi: 10.1093/ndt/gfy155.

PMID:
29905848
9.

Restrictive lung disorder is common in patients with kidney failure and associates with protein-energy wasting, inflammation and cardiovascular disease.

Mukai H, Ming P, Lindholm B, Heimbürger O, Barany P, Anderstam B, Stenvinkel P, Qureshi AR.

PLoS One. 2018 Apr 27;13(4):e0195585. doi: 10.1371/journal.pone.0195585. eCollection 2018.

10.

Lung Dysfunction and Mortality in Patients with Chronic Kidney Disease.

Mukai H, Ming P, Lindholm B, Heimbürger O, Barany P, Stenvinkel P, Qureshi AR.

Kidney Blood Press Res. 2018;43(2):522-535. doi: 10.1159/000488699. Epub 2018 Mar 29.

11.

Skin autofluorescence, arterial stiffness and Framingham risk score as predictors of clinical outcome in chronic kidney disease patients: a cohort study.

Mukai H, Svedberg O, Lindholm B, Dai L, Heimbürger O, Barany P, Anderstam B, Stenvinkel P, Qureshi AR.

Nephrol Dial Transplant. 2019 Mar 1;34(3):442-448. doi: 10.1093/ndt/gfx371.

PMID:
29378035
12.

The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease.

Alves FC, Sun J, Qureshi AR, Dai L, Snaedal S, Bárány P, Heimbürger O, Lindholm B, Stenvinkel P.

PLoS One. 2018 Jan 3;13(1):e0190410. doi: 10.1371/journal.pone.0190410. eCollection 2018.

13.

Why do physicians prescribe dialysis? A prospective questionnaire study.

Heaf J, Petersons A, Vernere B, Heiro M, Povlsen JV, Sørensen AB, Rosenberg M, Løkkegaard N, Alonso-Garcia F, Kampmann JD, Clyne N, Randers E, Heimburger O, Lindholm B.

PLoS One. 2017 Dec 20;12(12):e0188309. doi: 10.1371/journal.pone.0188309. eCollection 2017.

14.

Clinical global assessment of nutritional status as predictor of mortality in chronic kidney disease patients.

Dai L, Mukai H, Lindholm B, Heimbürger O, Barany P, Stenvinkel P, Qureshi AR.

PLoS One. 2017 Dec 6;12(12):e0186659. doi: 10.1371/journal.pone.0186659. eCollection 2017.

15.

Plasma Beta-Trace Protein as a Marker of Residual Renal Function: The Effect of Different Hemodialysis Modalities and Intra-Individual Variability over Time.

van Craenenbroeck AH, Bragfors-Helin AC, Qureshi AR, Lindholm B, Sjöberg B, Anderstam B, Heimburger O, Stenvinkel P, Bárány P.

Kidney Blood Press Res. 2017;42(5):877-885. doi: 10.1159/000484537. Epub 2017 Nov 22.

16.

Does statins promote vascular calcification in chronic kidney disease?

Chen Z, Qureshi AR, Parini P, Hurt-Camejo E, Ripsweden J, Brismar TB, Barany P, Jaminon AM, Schurgers LJ, Heimbürger O, Lindholm B, Stenvinkel P.

Eur J Clin Invest. 2017 Feb;47(2):137-148. doi: 10.1111/eci.12718.

PMID:
28036114
17.

Plasma Pentosidine and Its Association with Mortality in Patients with Chronic Kidney Disease.

Machowska A, Sun J, Qureshi AR, Isoyama N, Leurs P, Anderstam B, Heimburger O, Barany P, Stenvinkel P, Lindholm B.

PLoS One. 2016 Oct 4;11(10):e0163826. doi: 10.1371/journal.pone.0163826. eCollection 2016.

18.

Do metabolic derangements in end-stage polycystic kidney disease differ versus other primary kidney diseases?

Jankowska M, Qureshi AR, Barany P, Heimburger O, Stenvinkel P, Lindholm B.

Nephrology (Carlton). 2018 Jan;23(1):31-36. doi: 10.1111/nep.12927.

PMID:
27653449
19.

Vertebral bone density associates with coronary artery calcification and is an independent predictor of poor outcome in end-stage renal disease patients.

Chen Z, Qureshi AR, Ripsweden J, Wennberg L, Heimburger O, Lindholm B, Barany P, Haarhaus M, Brismar TB, Stenvinkel P.

Bone. 2016 Nov;92:50-57. doi: 10.1016/j.bone.2016.08.007. Epub 2016 Aug 9.

PMID:
27519971
20.

Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD.

Sun J, Axelsson J, Machowska A, Heimbürger O, Bárány P, Lindholm B, Lindström K, Stenvinkel P, Qureshi AR.

Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1163-72. doi: 10.2215/CJN.10441015. Epub 2016 Jun 8.

21.

Dialysis modality and nutritional status are associated with variability of inflammatory markers.

Snaedal S, Qureshi AR, Lund SH, Germanis G, Hylander B, Heimbürger O, Carrero JJ, Stenvinkel P, Bárány P.

Nephrol Dial Transplant. 2016 Aug;31(8):1320-7. doi: 10.1093/ndt/gfw104. Epub 2016 May 24.

PMID:
27220753
22.

Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis.

Bergman A, Qureshi AR, Haarhaus M, Lindholm B, Barany P, Heimburger O, Stenvinkel P, Anderstam B.

J Nephrol. 2017 Apr;30(2):255-262. doi: 10.1007/s40620-016-0292-7. Epub 2016 Mar 18.

PMID:
26994005
23.

A cohort study of insulin-like growth factor 1 and mortality in haemodialysis patients.

Nilsson E, Carrero JJ, Heimbürger O, Hellberg O, Lindholm B, Stenvinkel P.

Clin Kidney J. 2016 Feb;9(1):148-52. doi: 10.1093/ckj/sfv118. Epub 2015 Nov 26.

24.

Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease.

Missailidis C, Hällqvist J, Qureshi AR, Barany P, Heimbürger O, Lindholm B, Stenvinkel P, Bergman P.

PLoS One. 2016 Jan 11;11(1):e0141738. doi: 10.1371/journal.pone.0141738. eCollection 2016.

25.

Elevated Circulating S100A12 Associates with Vascular Disease and Worse Clinical Outcome in Peritoneal Dialysis Patients.

Isoyama N, Machowska A, Qureshi AR, Yamamoto T, Anderstam B, Heimburger O, Barany P, Stenvinkel P, Lindholm B.

Perit Dial Int. 2016 May-Jun;36(3):269-76. doi: 10.3747/pdi.2014.00121. Epub 2015 Oct 22.

26.

Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly.

Sjöberg B, Qureshi AR, Heimbürger O, Stenvinkel P, Lind L, Larsson A, Bárány P, Ärnlöv J.

J Intern Med. 2016 Feb;279(2):173-9. doi: 10.1111/joim.12411. Epub 2015 Sep 9.

27.

Three-month variation of plasma pentraxin 3 compared with C-reactive protein, albumin and homocysteine levels in haemodialysis patients.

Sjöberg B, Snaedal S, Stenvinkel P, Qureshi AR, Heimbürger O, Bárány P.

Clin Kidney J. 2014 Aug;7(4):373-9. doi: 10.1093/ckj/sfu071.

28.

Delta-He: a novel marker of inflammation predicting mortality and ESA response in peritoneal dialysis patients.

Danielson K, Beshara S, Qureshi AR, Heimbürger O, Lindholm B, Hansson M, Hylander B, Germanis G, Stenvinkel P, Barany P.

Clin Kidney J. 2014 Jun;7(3):275-81. doi: 10.1093/ckj/sfu038. Epub 2014 May 14.

29.

Clinical determinants of reduced physical activity in hemodialysis and peritoneal dialysis patients.

Cobo G, Gallar P, Gama-Axelsson T, Di Gioia C, Qureshi AR, Camacho R, Vigil A, Heimbürger O, Ortega O, Rodriguez I, Herrero JC, Bárány P, Lindholm B, Stenvinkel P, Carrero JJ.

J Nephrol. 2015 Aug;28(4):503-10. doi: 10.1007/s40620-014-0164-y. Epub 2014 Dec 12.

PMID:
25501981
30.

Dialysis modality choice in diabetic patients with end-stage kidney disease: a systematic review of the available evidence.

Couchoud C, Bolignano D, Nistor I, Jager KJ, Heaf J, Heimburger O, Van Biesen W; European Renal Best Practice (ERBP) Diabetes Guideline Development Group.

Nephrol Dial Transplant. 2015 Feb;30(2):310-20. doi: 10.1093/ndt/gfu293. Epub 2014 Sep 23. Review.

PMID:
25248364
31.

Comparative associations of muscle mass and muscle strength with mortality in dialysis patients.

Isoyama N, Qureshi AR, Avesani CM, Lindholm B, Bàràny P, Heimbürger O, Cederholm T, Stenvinkel P, Carrero JJ.

Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1720-8. doi: 10.2215/CJN.10261013. Epub 2014 Jul 29.

32.

Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.

Isoyama N, Leurs P, Qureshi AR, Bruchfeld A, Anderstam B, Heimburger O, Bárány P, Stenvinkel P, Lindholm B.

Nephrol Dial Transplant. 2015 Jan;30(1):84-91. doi: 10.1093/ndt/gfu259. Epub 2014 Jul 28.

PMID:
25074436
33.

The use of estimated glomerular filtration rate for dose adjustment of medications in the elderly.

Elinder CG, Bárány P, Heimbürger O.

Drugs Aging. 2014 Jul;31(7):493-9. doi: 10.1007/s40266-014-0187-z. Review.

PMID:
24902935
34.

Determinants of N-terminal pro-brain natriuretic peptide variation in hemodialysis patients and prediction of survival.

Snaedal S, Qureshi AR, Carrero JJ, Heimbürger O, Stenvinkel P, Bárány P.

Blood Purif. 2014;37(2):138-45. doi: 10.1159/000360267. Epub 2014 Apr 8.

PMID:
24732340
35.

Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients.

Xu H, Watanabe M, Qureshi AR, Heimbürger O, Bárány P, Anderstam B, Eriksson M, Stenvinkel P, Lindholm B.

Perit Dial Int. 2015 Mar-Apr;35(2):206-15. doi: 10.3747/pdi.2013.00259. Epub 2014 Mar 1.

36.

Increased Levels of Modified Advanced Oxidation Protein Products Are Associated with Central and Peripheral Blood Pressure in Peritoneal Dialysis Patients.

Xu H, Cabezas-Rodriguez I, Qureshi AR, Heimburger O, Barany P, Snaedal S, Anderstam B, Helin AC, Carrero JJ, Stenvinkel P, Lindholm B.

Perit Dial Int. 2015 Jul-Aug;35(4):460-70. doi: 10.3747/pdi.2013.00064. Epub 2014 Mar 1.

37.

Selection of genetic and phenotypic features associated with inflammatory status of patients on dialysis using relaxed linear separability method.

Bobrowski L, Łukaszuk T, Lindholm B, Stenvinkel P, Heimburger O, Axelsson J, Bárány P, Carrero JJ, Qureshi AR, Luttropp K, Debowska M, Nordfors L, Schalling M, Waniewski J.

PLoS One. 2014 Jan 28;9(1):e86630. doi: 10.1371/journal.pone.0086630. eCollection 2014.

38.

[It is better use a modern formula than being formal].

Elinder CG, Bárány P, Heimbürger O.

Lakartidningen. 2013 Nov 20-26;110(47):2122. Swedish. No abstract available.

PMID:
24437105
39.

[Drug dosage should be based on renal function].

Elinder CG, Bárány P, Heimbürger O.

Lakartidningen. 2013 Nov 20-26;110(47):2119-20. Swedish. No abstract available.

PMID:
24437103
40.

Subclinical versus overt obesity in dialysis patients: more than meets the eye.

Gracia-Iguacel C, Qureshi AR, Avesani CM, Heimbürger O, Huang X, Lindholm B, Bárány P, Ortiz A, Stenvinkel P, Carrero JJ.

Nephrol Dial Transplant. 2013 Nov;28 Suppl 4:iv175-81. doi: 10.1093/ndt/gft024.

PMID:
24179011
41.

IGF-1 and survival in ESRD.

Jia T, Gama Axelsson T, Heimbürger O, Bárány P, Lindholm B, Stenvinkel P, Qureshi AR.

Clin J Am Soc Nephrol. 2014 Jan;9(1):120-7. doi: 10.2215/CJN.02470213. Epub 2013 Oct 31.

42.

Serum hepatocyte growth factor is associated with truncal fat mass and increased mortality in chronic kidney disease stage 5 patients with protein-energy wasting.

Yuan J, Watanabe M, Suliman M, Qureshi AR, Axelsson J, Bárány P, Heimbürger O, Stenvinkel P, Lindholm B.

Nephrol Dial Transplant. 2015 Feb;30(2):274-82. doi: 10.1093/ndt/gft265. Epub 2013 Aug 24.

PMID:
23975839
43.

Immunoglobulin (Ig)M antibodies against oxidized cardiolipin but not native cardiolipin are novel biomarkers in haemodialysis patients, associated negatively with mortality.

Frostegård AG, Hua X, Su J, Carrero JJ, Heimbürger O, Bárány P, Stenvinkel P, Frostegård J.

Clin Exp Immunol. 2013 Dec;174(3):441-8. doi: 10.1111/cei.12181.

44.

Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients.

Yuan J, Guo Q, Qureshi AR, Anderstam B, Eriksson M, Heimbürger O, Bárány P, Stenvinkel P, Lindholm B.

Nephrol Dial Transplant. 2013 Sep;28(9):2356-63. doi: 10.1093/ndt/gft256. Epub 2013 Jul 4.

PMID:
23828162
45.

Nonthyroidal illness: a risk factor for coronary calcification and arterial stiffness in patients undergoing peritoneal dialysis?

Meuwese CL, Carrero JJ, Cabezas-Rodríguez I, Heimburger O, Barany P, Lindholm B, Qureshi AR, Ripsweden J, Dekker FW, Stenvinkel P.

J Intern Med. 2013 Dec;274(6):584-93. doi: 10.1111/joim.12107. Epub 2013 Jul 15.

46.

Determinants of fibroblast growth factor-23 and parathyroid hormone variability in dialysis patients.

Jia T, Qureshi AR, Brandenburg V, Ketteler M, Barany P, Heimburger O, Uhlin F, Magnusson P, Fernström A, Lindholm B, Stenvinkel P, Larsson TE.

Am J Nephrol. 2013;37(5):462-71. doi: 10.1159/000350537. Epub 2013 Apr 27.

PMID:
23635517
47.

Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4.

Ghanavatian S, Diep LM, Bárány P, Heimbürger O, Seeberger A, Stenvinkel P, Rohani M, Agewall S.

Angiology. 2014 May;65(5):443-9. doi: 10.1177/0003319713483000. Epub 2013 Apr 7.

PMID:
23567479
48.

The enigma of decreased creatinine generation in acute kidney injury.

Heimbürger O, Stenvinkel P, Bárány P.

Nephrol Dial Transplant. 2012 Nov;27(11):3973-4. doi: 10.1093/ndt/gfs459. No abstract available.

PMID:
23144066
49.

Determinants and survival implications of low bone mineral density in end-stage renal disease patients.

Park SH, Jia T, Qureshi AR, Bárány P, Heimbürger O, Larsson TE, Axelsson J, Stenvinkel P, Lindholm B.

J Nephrol. 2013 May-Jun;26(3):485-94. doi: 10.5301/jn.5000185. Epub 2012 Sep 13.

PMID:
22976520
50.

Clinical determinants and mortality predictability of stearoyl-CoA desaturase-1 activity indices in dialysis patients.

Huang X, Stenvinkel P, Qureshi AR, Cederholm T, Bárány P, Heimbürger O, Lindholm B, Risérus U, Carrero JJ.

J Intern Med. 2013 Mar;273(3):263-72. doi: 10.1111/j.1365-2796.2012.02573.x. Epub 2012 Aug 20.

Supplemental Content

Loading ...
Support Center